GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Shiller PE Ratio

89bio (ETNB) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is 89bio Shiller PE Ratio?

89bio does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


89bio Shiller PE Ratio Historical Data

The historical data trend for 89bio's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Shiller PE Ratio Chart

89bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial - - - - -

89bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 89bio's Shiller PE Ratio

For the Biotechnology subindustry, 89bio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


89bio's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 89bio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where 89bio's Shiller PE Ratio falls into.



89bio Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

89bio does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


89bio  (NAS:ETNB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


89bio Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of 89bio's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


89bio (ETNB) Business Description

Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
Kathleen Laporte director
Rohan Palekar director, officer: Chief Executive Officer 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Atkinson Edward Morrow Iii director C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Quoc Le-nguyen officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ryan Martins officer: Chief Financial Officer 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg director, 10 percent owner 100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz director, 10 percent owner 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026

89bio (ETNB) Headlines